FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FAM172A-FHIT

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FAM172A-FHIT
FusionPDB ID: 28700
FusionGDB2.0 ID: 28700
HgeneTgene
Gene symbol

FAM172A

FHIT

Gene ID

83989

2272

Gene namefamily with sequence similarity 172 member Afragile histidine triad diadenosine triphosphatase
SynonymsC5orf21|ToupeeAP3Aase|FRA3B
Cytomap

5q15

3p14.2

Type of geneprotein-codingprotein-coding
Descriptioncotranscriptional regulator FAM172Aprotein FAM172Abis(5'-adenosyl)-triphosphataseAP3A hydrolasediadenosine 5',5'''-P1,P3-triphosphate hydrolasedinucleosidetriphosphatase
Modification date2020031320200313
UniProtAcc

Q8WUF8

Main function of 5'-partner protein: FUNCTION: Plays a role in the regulation of alternative splicing, by interacting with AGO2 and CHD7. Seems to be required for stabilizing protein-protein interactions at the chromatin-spliceosome interface. May have hydrolase activity. {ECO:0000250|UniProtKB:Q3TNH5}.

P49789

Main function of 5'-partner protein: FUNCTION: Possesses dinucleoside triphosphate hydrolase activity (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9576908, PubMed:9543008). Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9576908, PubMed:9543008). Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP (PubMed:8794732). Exhibits adenylylsulfatase activity, hydrolyzing adenosine 5'-phosphosulfate to yield AMP and sulfate (PubMed:18694747). Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:18694747). Exhibits adenylylsulfate-ammonia adenylyltransferase, catalyzing the ammonolysis of adenosine 5'-phosphosulfate resulting in the formation of adenosine 5'-phosphoramidate (PubMed:26181368). Also catalyzes the ammonolysis of adenosine 5-phosphorofluoridate and diadenosine triphosphate (PubMed:26181368). Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5 (PubMed:18077326). Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways (PubMed:16407838). Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis (PubMed:15313915). Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake (PubMed:12574506, PubMed:19622739). Functions as tumor suppressor (By similarity). {ECO:0000250|UniProtKB:O89106, ECO:0000269|PubMed:12574506, ECO:0000269|PubMed:15313915, ECO:0000269|PubMed:16407838, ECO:0000269|PubMed:18077326, ECO:0000269|PubMed:18694747, ECO:0000269|PubMed:19622739, ECO:0000269|PubMed:26181368, ECO:0000269|PubMed:8794732, ECO:0000269|PubMed:9323207, ECO:0000269|PubMed:9543008}.
Ensembl transtripts involved in fusion geneENST idsENST00000395965, ENST00000509163, 
ENST00000504768, ENST00000505869, 
ENST00000509739, 		ENST00000341848, 
ENST00000466788, ENST00000468189, 
ENST00000476844, ENST00000492590, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score18 X 17 X 8=244827 X 20 X 11=5940
# samples 2332
** MAII scorelog2(23/2448*10)=-3.41189779174828
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(32/5940*10)=-4.21431912080077
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: FAM172A [Title/Abstract] AND FHIT [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FAM172A [Title/Abstract] AND FHIT [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FAM172A(93294482)-FHIT(59738047), # samples:3
Anticipated loss of major functional domain due to fusion event.FAM172A-FHIT seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FAM172A-FHIT seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FAM172A-FHIT seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
FAM172A-FHIT seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
FAM172A-FHIT seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
FAM172A-FHIT seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneFHIT

GO:0006163

purine nucleotide metabolic process

9323207



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:93294482/chr3:59738047)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FAM172A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across FHIT (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000395965FAM172Achr593294482-ENST00000476844FHITchr359738047-1070710140805221
ENST00000395965FAM172Achr593294482-ENST00000492590FHITchr359738047-1081710140805221

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000395965ENST00000476844FAM172Achr593294482-FHITchr359738047-0.0033691950.99663085
ENST00000395965ENST00000492590FAM172Achr593294482-FHITchr359738047-0.003284970.99671507

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FAM172A-FHIT

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FAM172Achr593294482FHITchr359738047710190SGTQIPFIKRAVALQKHDKEDFPASW

Top

Potential FusionNeoAntigen Information of FAM172A-FHIT in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FAM172A-FHIT_93294482_59738047.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FAM172A-FHITchr593294482chr359738047710HLA-B08:01FIKRAVAL0.99980.6458614
FAM172A-FHITchr593294482chr359738047710HLA-B08:09FIKRAVAL0.99960.749614
FAM172A-FHITchr593294482chr359738047710HLA-B08:01IPFIKRAVAL0.99570.7953414
FAM172A-FHITchr593294482chr359738047710HLA-B08:09IPFIKRAVAL0.99380.778414
FAM172A-FHITchr593294482chr359738047710HLA-B35:03IPFIKRAVAL0.92340.9416414
FAM172A-FHITchr593294482chr359738047710HLA-B35:02IPFIKRAVAL0.84060.9687414
FAM172A-FHITchr593294482chr359738047710HLA-B35:04IPFIKRAVAL0.84060.9687414
FAM172A-FHITchr593294482chr359738047710HLA-B42:02IPFIKRAVAL0.99560.7966414
FAM172A-FHITchr593294482chr359738047710HLA-B42:01IPFIKRAVAL0.99530.7881414
FAM172A-FHITchr593294482chr359738047710HLA-B07:12IPFIKRAVAL0.98320.5959414
FAM172A-FHITchr593294482chr359738047710HLA-B39:10IPFIKRAVAL0.86420.9689414
FAM172A-FHITchr593294482chr359738047710HLA-B35:12IPFIKRAVAL0.84060.9687414
FAM172A-FHITchr593294482chr359738047710HLA-B08:18FIKRAVAL0.99980.6458614
FAM172A-FHITchr593294482chr359738047710HLA-B08:12FIKRAVAL0.98090.7846614
FAM172A-FHITchr593294482chr359738047710HLA-B27:10KRAVALQKH0.99890.8736817
FAM172A-FHITchr593294482chr359738047710HLA-B08:18IPFIKRAVAL0.99570.7953414
FAM172A-FHITchr593294482chr359738047710HLA-B08:12IPFIKRAVAL0.97140.8773414
FAM172A-FHITchr593294482chr359738047710HLA-B78:02IPFIKRAVAL0.91310.5013414
FAM172A-FHITchr593294482chr359738047710HLA-B67:01IPFIKRAVAL0.87860.9125414
FAM172A-FHITchr593294482chr359738047710HLA-B35:09IPFIKRAVAL0.84060.9687414

Top

Potential FusionNeoAntigen Information of FAM172A-FHIT in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FAM172A-FHIT_93294482_59738047.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FAM172A-FHITchr593294482chr359738047710DRB1-0802QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0802TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-0809QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0809TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-0813QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0815QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0815TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-0821QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0821TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-0830QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-0830TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-1130QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1145QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1343AVALQKHDKEDFPAS1025
FAM172A-FHITchr593294482chr359738047710DRB1-1347QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1367QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1403QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1416AVALQKHDKEDFPAS1025
FAM172A-FHITchr593294482chr359738047710DRB1-1427QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1427TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-1440QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1467QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1467TQIPFIKRAVALQKH217
FAM172A-FHITchr593294482chr359738047710DRB1-1477QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB1-1498QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB4-0101KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0101IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0101FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0101RAVALQKHDKEDFPA924
FAM172A-FHITchr593294482chr359738047710DRB4-0103KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0103IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0103FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0103RAVALQKHDKEDFPA924
FAM172A-FHITchr593294482chr359738047710DRB4-0104KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0104IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0104FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0106KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0106IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0106FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0106RAVALQKHDKEDFPA924
FAM172A-FHITchr593294482chr359738047710DRB4-0107KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0107IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0107FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0107RAVALQKHDKEDFPA924
FAM172A-FHITchr593294482chr359738047710DRB4-0108KRAVALQKHDKEDFP823
FAM172A-FHITchr593294482chr359738047710DRB4-0108IKRAVALQKHDKEDF722
FAM172A-FHITchr593294482chr359738047710DRB4-0108FIKRAVALQKHDKED621
FAM172A-FHITchr593294482chr359738047710DRB4-0108RAVALQKHDKEDFPA924
FAM172A-FHITchr593294482chr359738047710DRB5-0101IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0101QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0101PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0102IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0102QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0103IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0103QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0104IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0104QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0104PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0105IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0105QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0105PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0106IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0106QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0106PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0108NIPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0108NQIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0111IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0111QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0112IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0112QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0113IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0113QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0113PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0114IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0114QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0114PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0202IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0202QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0203IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0204IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0204QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0204PFIKRAVALQKHDKE520
FAM172A-FHITchr593294482chr359738047710DRB5-0205IPFIKRAVALQKHDK419
FAM172A-FHITchr593294482chr359738047710DRB5-0205QIPFIKRAVALQKHD318
FAM172A-FHITchr593294482chr359738047710DRB5-0205PFIKRAVALQKHDKE520

Top

Fusion breakpoint peptide structures of FAM172A-FHIT

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2415FIKRAVALQKHDKEFAM172AFHITchr593294482chr359738047710

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FAM172A-FHIT

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2415FIKRAVALQKHDKE-7.9962-8.1096
HLA-B14:023BVN2415FIKRAVALQKHDKE-5.70842-6.74372
HLA-B52:013W392415FIKRAVALQKHDKE-6.83737-6.95077
HLA-B52:013W392415FIKRAVALQKHDKE-4.4836-5.5189
HLA-A11:014UQ22415FIKRAVALQKHDKE-10.0067-10.1201
HLA-A11:014UQ22415FIKRAVALQKHDKE-9.03915-10.0745
HLA-A24:025HGA2415FIKRAVALQKHDKE-6.56204-6.67544
HLA-A24:025HGA2415FIKRAVALQKHDKE-5.42271-6.45801
HLA-B44:053DX82415FIKRAVALQKHDKE-7.85648-8.89178
HLA-B44:053DX82415FIKRAVALQKHDKE-5.3978-5.5112
HLA-A02:016TDR2415FIKRAVALQKHDKE-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of FAM172A-FHIT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FAM172A-FHITchr593294482chr359738047414IPFIKRAVALATACCGTTTATTAAAAGAGCTGTGGCTCTC
FAM172A-FHITchr593294482chr359738047614FIKRAVALTTTATTAAAAGAGCTGTGGCTCTC
FAM172A-FHITchr593294482chr359738047817KRAVALQKHAAAAGAGCTGTGGCTCTCCAGAAACAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
FAM172A-FHITchr593294482chr3597380471025AVALQKHDKEDFPASGCTGTGGCTCTCCAGAAACATGACAAGGAGGACTTTCCTGCCTCT
FAM172A-FHITchr593294482chr359738047217TQIPFIKRAVALQKHACACAGATACCGTTTATTAAAAGAGCTGTGGCTCTCCAGAAACAT
FAM172A-FHITchr593294482chr359738047318QIPFIKRAVALQKHDCAGATACCGTTTATTAAAAGAGCTGTGGCTCTCCAGAAACATGAC
FAM172A-FHITchr593294482chr359738047419IPFIKRAVALQKHDKATACCGTTTATTAAAAGAGCTGTGGCTCTCCAGAAACATGACAAG
FAM172A-FHITchr593294482chr359738047520PFIKRAVALQKHDKECCGTTTATTAAAAGAGCTGTGGCTCTCCAGAAACATGACAAGGAG
FAM172A-FHITchr593294482chr359738047621FIKRAVALQKHDKEDTTTATTAAAAGAGCTGTGGCTCTCCAGAAACATGACAAGGAGGAC
FAM172A-FHITchr593294482chr359738047722IKRAVALQKHDKEDFATTAAAAGAGCTGTGGCTCTCCAGAAACATGACAAGGAGGACTTT
FAM172A-FHITchr593294482chr359738047823KRAVALQKHDKEDFPAAAAGAGCTGTGGCTCTCCAGAAACATGACAAGGAGGACTTTCCT
FAM172A-FHITchr593294482chr359738047924RAVALQKHDKEDFPAAGAGCTGTGGCTCTCCAGAAACATGACAAGGAGGACTTTCCTGCC

Top

Information of the samples that have these potential fusion neoantigens of FAM172A-FHIT

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
KIRCFAM172A-FHITchr593294482ENST00000395965chr359738047ENST00000476844TCGA-B2-4101-01A

Top

Potential target of CAR-T therapy development for FAM172A-FHIT

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FAM172A-FHIT

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FAM172A-FHIT

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneFHITC0024121Lung Neoplasms2CTD_human
TgeneFHITC0025500Mesothelioma2CTD_human
TgeneFHITC0242379Malignant neoplasm of lung2CTD_human
TgeneFHITC0007097Carcinoma1CTD_human
TgeneFHITC0007131Non-Small Cell Lung Carcinoma1CTD_human
TgeneFHITC0013146Drug abuse1CTD_human
TgeneFHITC0013170Drug habituation1CTD_human
TgeneFHITC0013222Drug Use Disorders1CTD_human
TgeneFHITC0023903Liver neoplasms1CTD_human
TgeneFHITC0024623Malignant neoplasm of stomach1CTD_human
TgeneFHITC0029231Organic Mental Disorders, Substance-Induced1CTD_human
TgeneFHITC0033578Prostatic Neoplasms1CTD_human
TgeneFHITC0038356Stomach Neoplasms1CTD_human
TgeneFHITC0038580Substance Dependence1CTD_human
TgeneFHITC0038586Substance Use Disorders1CTD_human
TgeneFHITC0042076Urologic Neoplasms1CTD_human
TgeneFHITC0205696Anaplastic carcinoma1CTD_human
TgeneFHITC0205697Carcinoma, Spindle-Cell1CTD_human
TgeneFHITC0205698Undifferentiated carcinoma1CTD_human
TgeneFHITC0205699Carcinomatosis1CTD_human
TgeneFHITC0236733Amphetamine-Related Disorders1CTD_human
TgeneFHITC0236804Amphetamine Addiction1CTD_human
TgeneFHITC0236807Amphetamine Abuse1CTD_human
TgeneFHITC0236969Substance-Related Disorders1CTD_human
TgeneFHITC0345904Malignant neoplasm of liver1CTD_human
TgeneFHITC0376358Malignant neoplasm of prostate1CTD_human
TgeneFHITC0740858Substance abuse problem1CTD_human
TgeneFHITC0751571Cancer of Urinary Tract1CTD_human
TgeneFHITC1510472Drug Dependence1CTD_human
TgeneFHITC1708349Hereditary Diffuse Gastric Cancer1CTD_human
TgeneFHITC4316881Prescription Drug Abuse1CTD_human